Physician profile
Leo L Chen
NPI 1598926255
$9,340.82
in general payments reported to CMS, 2019-2025
20 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2021: $496 · 2022: $1,276 · 2023: $1,945 · 2024: $3,015 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,953 · Travel and Lodging: $383 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,952.53 |
| Travel and Lodging | $382.82 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $1,753.37 | 2019-2025 | |
| Biogen, INC. | $1,512.49 | 2019-2025 | Spinraza, Skyclarys, Spinraza |
| Genentech, INC. | $920.45 | 2019-2025 | Ocrevus |
| Neurelis, INC. | $772.82 | 2021-2025 | Valtoco |
| Ucb, INC. | $703.09 | 2022-2025 | Fintepla, Briviact |
| Sk Life Science, INC. | $695.77 | 2022-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $522.85 | 2023-2025 | |
| Immedica Pharma US, INC. | $479.97 | 2023-2024 | |
| Genentech USA, INC. | $312.58 | 2023-2024 | Ocrevus, Evrysdi |
| Livanova USA, INC. | $280.61 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Zogenix INC. | $197.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $195.98 | 2023 | |
| Medtronic, INC. | $192.12 | 2025 | Percept PC Brainsense, Catalyft Pl Expandable Interbody System |
| Celgene Corporation | $140.31 | 2019 | |
| Eisai INC. | $125.00 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.99 | 2019 | |
| Greenwich Biosciences, INC. | $124.01 | 2019 | |
| Alexion Pharmaceuticals, INC. | $116.01 | 2025 | Ultomiris |
| Impel Pharmaceuticals INC. | $100.97 | 2022 | |
| Genzyme Corporation | $69.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.